3 - Fresh2 Group Ltd (0001786511) (Issuer)

3 - Fresh2 Group Ltd (0001786511) (Issuer)

3 - Fresh2 Group Ltd (0001786511) (Issuer)

3 - Fresh2 Group Ltd (0001786511) (Issuer)

3 - Fresh2 Group Ltd (0001786511) (Issuer)

3/A - Fresh2 Group Ltd (0001786511) (Issuer)

3 - Fresh2 Group Ltd (0001786511) (Issuer)

NEW YORK, Feb. 15, 2023 /PRNewswire/ -- AnPac Bio-Medical Science Co., Ltd. (the "Company") (NASDAQ:ANPC), a company with operations in the United States and China focused on early cancer screening and detection and plans to enter into the operation of a business-to-business e-commerce food platform focused on the sale of Asian sourced food products, announced the closing of the acquisition of GISN (HK) LIMITED ("GISN"), a technical solution and outsourcing consulting services provider focused on the digital, internet and Web 3 business transformation for start-ups and traditional enterprises. This acquisition is a critical initiative for the Company to improve the efficiency of its e-commer

Ticker symbol change effective at the market open May 22, 2023 NEW YORK, May 19, 2023 /PRNewswire/ -- Fresh2 Group Ltd., formerly AnPac Bio-Medical Science Co., Ltd. (NASDAQ: ANPC), a company with operations in the United States and China focused on early cancer screening and detection and plans to enter into the operation of  a business-to-business e-commerce food platform focused on the sale of Asian sourced food products, today announced that its ticker symbol on the Nasdaq Stock Market ("Nasdaq") will change to "FRES" effective at the open of market trading on May 22, 2023 following the Company's name change from AnPac Bio-Medical Science Co., Ltd to Fresh2 Group Ltd. The Company has tra

NEW YORK, May 16, 2023 /PRNewswire/ -- Fresh2 Group Limited (Formerly AnPac Bio-Medical Science Co., Ltd., "Fresh2," the "Company" or "we") (NASDAQ:ANPC), a company with operations in the United States and China focused on early cancer screening and detection and entering into the operation of a business-to-business e-commerce food platform focused on the sale of Asian sourced food products, today announced that it filed its annual report on Form 20-F for the fiscal year ended December 31, 2022, with the U.S. Securities and Exchange Commission (the "SEC") on May 16, 2023. The annual report on Form 20-F can be accessed on the SEC's website at http://www.sec.gov and the Company's investor rela

NEW YORK, May 16, 2023 /PRNewswire/ -- Fresh2 Group Limited (Formerly AnPac Bio-Medical Science Co., Ltd. ,"Fresh2," the "Company" or "we") (NASDAQ:ANPC), a company with operations in the United States and China focused on early cancer screening and detection and entering into the operation of a business-to-business e-commerce food platform focused on the sale of Asian sourced food products, announced today its annual financial results for the year ended December 31, 2022. Financial Highlights for Fiscal Year 2022 Total revenues were RMB12.0 million (US$1.7 million) in the year ended December 31, 2022, a decrease of 33.0% from RMB18.0 million in the year ended December 31, 2021.  Gross margi

NEW YORK, May 16, 2023 /PRNewswire/ -- Fresh2 Group Limited (Formerly AnPac Bio-Medical Science Co., Ltd., "Fresh2," the "Company" or "we") (NASDAQ:ANPC), a company with operations in the United States and China focused on early cancer screening and detection and entering into the operation of a business-to-business e-commerce food platform focused on the sale of Asian sourced food products, announced today its unaudited financial results for the first quarter ended March 31, 2023. The Company's financial statements and related financial information for the quarter ended March 31, 2023 are unaudited and have not been reviewed by the Company's independent registered accountant. These financia

New York, April 06, 2023 (GLOBE NEWSWIRE) -- Univest Securities, LLC ("Univest"), a member of FINRA and SIPC, and a full-service investment bank and securities broker-dealer firm based in New York, today announced the closing of registered direct offering (the "Offering") of 625,000 American Depositary Shares ("ADSs") priced at $4.00 per ADS, with pre-funded warrants exercisable for 125,000 ADSs and warrants exercisable for 750,000 ADSs for its client AnPac Bio-Medical Science Co., Ltd. (NASDAQ:ANPC) (the "Company" or "AnPac"), a company with operations in the United States and China focused on early cancer screening and detection and plans to enter into the operation of a business-to-busi

NEW YORK, April 6, 2023 /PRNewswire/-- AnPac Bio-Medical Science Co., Ltd. (the "Company") (NASDAQ:ANPC), a company with operations in the United States and China focused on early cancer screening and detection and plans to enter into the operation of a business-to-business e-commerce food platform focused on the sale of Asian sourced food products, today announced the closing of its previously announced registered direct offering pursuant to a securities purchase agreement with certain institutional investors to purchase $3.0 million of its American Depositary Shares ("ADSs"), pre-funded warrants to purchase ADSs and warrants to purchase ADSs.  The Company plans to use the net proceeds from

NEW YORK, April 3, 2023 /PRNewswire/ -- AnPac Bio-Medical Science Co., Ltd. (the "Company") (NASDAQ:ANPC), a company with operations in the United States and China focused on early cancer screening and detection and entering into the operation of a business-to-business e-commerce food platform focused on the sale of Asian sourced food products, announced that on March 31, 2023, the Company entered into an asset purchase agreement (the "Agreement") with Easy Hundred Inc. ("Easy Hundred"), a U.S.-based e-commerce company in the foodservice industry, through which the Company will acquire certain fixed assets of Easy Hundred and Easy Hundred's intellectual property relating to ez100, 2Supply an

New York, NY, March 31, 2023 (GLOBE NEWSWIRE) -- AnPac Bio-Medical Science Co., Ltd. (the "Company") (NASDAQ:ANPC), a company with operations in the United States and China focused on early cancer screening and detection and plans to enter into the operation of a business-to-business e-commerce food platform focused on the sale of Asian sourced food products, today announced that it has entered into a securities purchase agreement with certain institutional investors to purchase $3.0 million of its American Depositary Shares ("ADSs"), pre-funded warrants to purchase ADSs and warrants to purchase ADSs in a registered direct offering.  The Company plans to use the net proceeds from the offer

NEW YORK, March 23, 2023 /PRNewswire/ -- AnPac Bio-Medical Science Co., Ltd. (the "Company") (NASDAQ:ANPC), a company with operations in the United States and China focused on early cancer screening and detection and plans to enter into the operation of a business-to-business e-commerce food platform focused on the sale of Asian sourced food products, announced that on March 22, 2023, the Company has been notified by the Nasdaq Hearings Panel ("Panel") of the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") that the Company's request for continued listing on The Capital Market has been granted, subject to the requirement that the Company demonstrate on or before Ju

NEW YORK, March 7, 2023 /PRNewswire/ – AnPac Bio-Medical Science Co., Ltd. ("AnPac Bio" or the "Company" (Nasdaq: ANPC), a company with operations in the United States and China focused on early cancer screening and detection and plans to enter into the operation of a business-to-business e-commerce food platform focused on the sale of Asian sourced food products, announced today that it has received the first payment in late February 2023 from a Malaysian customer who had signed a US$1.5 million purchase contract for AnPac Bio's Model AP9080 cancer detection devices. The Model AP9080 cancer detection device is based on Company's patented, novel multi-cancer testing technology named Cancer D

AnPac Bio-Medical Science (NASDAQ:ANPC) reported quarterly losses of $(0.04) per share. This is a 99.46 percent increase over losses of $(7.40) per share from the same period last year. The company reported $87.00 thousand in sales this quarter. This is a 73.87 percent decrease over sales of $333.00 thousand the same period last year.

Gainers Biotricity (NASDAQ:BTCY) stock rose 30.2% to $0.73 during Tuesday's regular session. Trading volume for Biotricity's stock is 264.8K as of 13:30 EST. This is 121.2% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $38.3 million. TScan Therapeutics (NASDAQ:TCRX) shares moved upwards by 28.65% to $2.11. As of 13:30 EST, TScan Therapeutics's stock is trading at a volume of 57.1K, which is 136.6% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $51.9 million. Immatics (NASDAQ:IMTX) shares rose 26.93% to $9.29. Immatics's stock is trading at a volume of 3.3 million shares a

Gainers Bionomics (NASDAQ:BNOX) shares moved upwards by 62.8% to $2.93 during Friday's regular session. The current volume of 285.9K shares is 236.1% of Bionomics's average full-day volume over the last 100 days (last updated at 13:30 EST). The company's market cap stands at $23.9 million. Y-mAbs Therapeutics (NASDAQ:YMAB) shares increased by 53.49% to $5.05. As of 13:30 EST, this security is trading at a volume of 15.4 million shares, making up 4939.0% of its average full-day volume over the last 100 days. The company's market cap stands at $220.5 million. As per the press release, Q4 earnings came out yesterday. Brainstorm Cell (NASDAQ:BCLI) shares increased by 35.79% to $3.4. Brainstor

Gainers Y-mAbs Therapeutics, Inc (NASDAQ:YMAB) climbed 49.9% to $4.93 after the company posted a profit for the fourth quarter. Inpixon (NASDAQ:INPX) jumped 37.9% to $0.5101. Inpixon reported a 21% growth in revenue to $19.4 million for the 2022 fiscal year. Toro Corp. (NASDAQ:TORO) surged 31.6% to $3.12. Guardforce AI Co., Limited (NASDAQ:GFAI) gained 27% to $6.00. IonQ, Inc. (NYSE:IONQ) rose 25.8% to $6.39 after clocking upbeat fourth-quarter results. FOXO Technologies Inc. (NASDAQ:FOXO) gained 24.4% to $0.4612 following full year 2022 results. Metropolitan Bank Holding Corp. (NYSE:MCB) gained 23% to $31.18 after the company issued updated financial information. Palisade Bio, Inc

AnPac Bio-Medical Science Co., Ltd. (NASDAQ:ANPC) ("AnPac Bio," the "Company" or "we"), a company with operations in the United States and China focused on early cancer screening and detection and plans to enter into the operation of a business-to-business e-commerce food platform focused on the sale of Asian sourced food products, announced that on March 2023, the Company has entered into definitive investment agreements with certain accredited investors in a private placement transaction, pursuant to which the investors agreed to subscribe for and purchase, and the Company agreed to issue and sell an aggregate of 16,666,665 newly issued Class A ordinary shares of the Company, at a price of

Health institutions including hospitals have reported that 2,837 individuals within the study were identified as cancer, pre-cancer and disease patients.  The confirmed cancer cases contained 22 types of cancer, with the top five confirmed cancer types being colorectal cancer, lung cancer, stomach cancer, prostatic cancer and breast cancer. The study also identified patients with esophageal cancer which does not have a bio-marker. The confirmed cases also include 27 types of pre-cancer.  Statistical analysis showed that there is also a strong correlation between CDA test score and cancer occurrence, with the higher the CDA value, the higher the cancer risk. If the enrolled individuals a